Reversible posterior leucoencephalopathy syndrome (RPLS) associated with pazopanib.

e15574 Background: Tyrosine kinase inhibitors (TKI) are a relatively new modality for the therapy of metastatic renal cell carcinoma (MRCC). Although there are promising results, their use is often limited due to adverse reactions. We report on a case of malignant hypertension (HTN) and RPLS in a patient (PT) treated with pazopanib for MRCC. Methods: Case report. Results: A 62 year old woman with MRCC and since 8 weeks under 3rd-line therapy with pazopanib had suddenly developed headaches, grand-mal seizures, paresis of the left arm, gait instability and nausea during her vacation. The emergency physician measured blood pressure (BP) values >300 mmHG systolic and suspected a stroke. A CT without contrast agent in a local hospital only showed bone metastases. Suspecting cerebral metastases or meningeosis carcinomatosa (MC) the colleagues referred her to our radiooncologic department for diagnostics and treatment planning. At admission the PT was somnolent and unable to communicate because she had received ...